342 related items for PubMed ID: 26697986
1. Any value of podocyte B7-1 as a biomarker in human MCD and FSGS?
Novelli R, Gagliardini E, Ruggiero B, Benigni A, Remuzzi G.
Am J Physiol Renal Physiol; 2016 Mar 01; 310(5):F335-41. PubMed ID: 26697986
[Abstract] [Full Text] [Related]
2. Ultrastructural features and expression of cytoskeleton proteins of podocyte from patients with minimal change disease and focal segmental glomerulosclerosis.
Shi SF, Wang SX, Zhang YK, Zhao MH, Zou WZ.
Ren Fail; 2008 Mar 01; 30(5):477-83. PubMed ID: 18569926
[Abstract] [Full Text] [Related]
3. Cell-cycle regulatory proteins in the podocyte in collapsing glomerulopathy in children.
Srivastava T, Garola RE, Singh HK.
Kidney Int; 2006 Aug 01; 70(3):529-35. PubMed ID: 16775597
[Abstract] [Full Text] [Related]
4. CD80 expression and infiltrating regulatory T cells in idiopathic nephrotic syndrome of childhood.
Eroglu FK, Orhan D, İnözü M, Duzova A, Gulhan B, Ozaltin F, Topaloglu R.
Pediatr Int; 2019 Dec 01; 61(12):1250-1256. PubMed ID: 31513327
[Abstract] [Full Text] [Related]
5. In situ evaluation of podocytes in patients with focal segmental glomerulosclerosis and minimal change disease.
da Silva CA, Monteiro MLGDR, Araújo LS, Urzedo MG, Rocha LB, Dos Reis MA, Machado JR.
PLoS One; 2020 Dec 01; 15(11):e0241745. PubMed ID: 33147279
[Abstract] [Full Text] [Related]
6. Reduced INF2 expression in nephrotic syndrome is possibly related to clinical severity of steroid resistance in children.
Tamura H, Nakazato H, Kuraoka S, Yoneda K, Takahashi W, Endo F.
Nephrology (Carlton); 2016 Jun 01; 21(6):467-75. PubMed ID: 26383224
[Abstract] [Full Text] [Related]
7. Messenger RNA expression of B7-1 and NPHS1 in urinary sediment could be useful to differentiate between minimal-change disease and focal segmental glomerulosclerosis in adult patients.
Navarro-Muñoz M, Ibernon M, Pérez V, Ara J, Espinal A, López D, Bonet J, Romero R.
Nephrol Dial Transplant; 2011 Dec 01; 26(12):3914-23. PubMed ID: 21414970
[Abstract] [Full Text] [Related]
8. [The clinic significance of urinary podocytes in patients with focal segmental glomerulosclerosis].
Li YH, Huang HC, Liu G, Zhang YK.
Beijing Da Xue Xue Bao Yi Xue Ban; 2004 Apr 01; 36(2):135-8. PubMed ID: 15100729
[Abstract] [Full Text] [Related]
9. The role of B7-1 in proteinuria of glomerular origin.
Novelli R, Benigni A, Remuzzi G.
Nat Rev Nephrol; 2018 Sep 01; 14(9):589-596. PubMed ID: 29959373
[Abstract] [Full Text] [Related]
10. Clinical significance of fibroblast-specific protein-1 expression on podocytes in patients with focal segmental glomerulosclerosis.
Samejima K, Nakatani K, Suzuki D, Asai O, Sakan H, Yoshimoto S, Yamaguchi Y, Matsui M, Akai Y, Toyoda M, Iwano M, Saito Y.
Nephron Clin Pract; 2012 Sep 01; 120(1):c1-7. PubMed ID: 22126861
[Abstract] [Full Text] [Related]
11. Assessment of urinary angiotensinogen as a marker of podocyte injury in proteinuric nephropathies.
Eriguchi M, Yotsueda R, Torisu K, Kawai Y, Hasegawa S, Tanaka S, Noguchi H, Masutani K, Kitazono T, Tsuruya K.
Am J Physiol Renal Physiol; 2016 Feb 15; 310(4):F322-33. PubMed ID: 26632605
[Abstract] [Full Text] [Related]
12. CD80 and suPAR in patients with minimal change disease and focal segmental glomerulosclerosis: diagnostic and pathogenic significance.
Cara-Fuentes G, Wei C, Segarra A, Ishimoto T, Rivard C, Johnson RJ, Reiser J, Garin EH.
Pediatr Nephrol; 2014 Aug 15; 29(8):1363-71. PubMed ID: 24263531
[Abstract] [Full Text] [Related]
13. Glomerular malondialdehyde levels in patients with focal and segmental glomerulosclerosis and minimal change disease.
Nezhad ST, Momeni B, Basiratnia M.
Saudi J Kidney Dis Transpl; 2010 Sep 15; 21(5):886-91. PubMed ID: 20814126
[Abstract] [Full Text] [Related]
14. Urinary CD80 as a Replacement for Renal Biopsy for Diagnosis of Pediatric Minimal Change Disease.
Ahmed HM, Ezzat DA, Doudar NA, Adel M.
Iran J Kidney Dis; 2018 Mar 15; 12(2):107-111. PubMed ID: 29507273
[Abstract] [Full Text] [Related]
15. Podocin and uPAR are good biomarkers in cases of Focal and segmental glomerulosclerosis in pediatric renal biopsies.
Pereira LHM, da Silva CA, Monteiro MLGDR, Araújo LS, Rocha LP, Reis MBDR, Ramalho FS, Corrêa RRM, Silva MV, Reis MA, Machado JR.
PLoS One; 2019 Mar 15; 14(6):e0217569. PubMed ID: 31188898
[Abstract] [Full Text] [Related]
16. Efficacy of abatacept treatment for focal segmental glomerulosclerosis and minimal change disease: A systematic review of case reports, case series, and observational studies
.
Hansrivijit P, Puthenpura MM, Ghahramani N.
Clin Nephrol; 2020 Sep 15; 94(3):117-126. PubMed ID: 32589135
[Abstract] [Full Text] [Related]
17. Glomerular endothelial cells and podocytes can express CD80 in patients with minimal change disease during relapse.
Cara-Fuentes G, Venkatareddy M, Verma R, Segarra A, Cleuren AC, Martínez-Ramos A, Johnson RJ, Garg P.
Pediatr Nephrol; 2020 Oct 15; 35(10):1887-1896. PubMed ID: 32399663
[Abstract] [Full Text] [Related]
18. Minimal change disease and idiopathic FSGS: manifestations of the same disease.
Maas RJ, Deegens JK, Smeets B, Moeller MJ, Wetzels JF.
Nat Rev Nephrol; 2016 Dec 15; 12(12):768-776. PubMed ID: 27748392
[Abstract] [Full Text] [Related]
19. Ezrin--a useful factor in the prognosis of nephrotic syndrome in children: an immunohistochemical approach.
Ostalska-Nowicka D, Zachwieja J, Nowicki M, Kaczmarek E, Siwinska A, Witt M.
J Clin Pathol; 2006 Sep 15; 59(9):916-20. PubMed ID: 16522749
[Abstract] [Full Text] [Related]
20. Comparative differential proteomic analysis of minimal change disease and focal segmental glomerulosclerosis.
Pérez V, López D, Boixadera E, Ibernón M, Espinal A, Bonet J, Romero R.
BMC Nephrol; 2017 Feb 03; 18(1):49. PubMed ID: 28158993
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
